Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Belvarafenib · 1 trial · 1 indication
Severity determined according to National Cancer Institute Common Terminology Criteria for Adverse Events v5.0
| Arm | Type | Description |
|---|---|---|
| Belvarafenib Monotherapy | EXPERIMENTAL | Twice daily (BID), continuous dosing. |
| Belvarafenib Plus Cobimetinib | EXPERIMENTAL | Recommended dose (RD) and schedule of belvarafenib and cobimetinib selected based on the safety data, tolerability, pharmacokinetics, and anti-tumor activity tested in dose-finding phase followed by an expansion phase. |
| Belvarafenib Plus Cobimetinib Plus Nivolumab | EXPERIMENTAL | Recommended dose (RD) and schedule of belvarafenib and cobimetinib plus nivolumab IV infusion every 4 weeks (Q4W) in a run-in phase followed by an expansion phase |
| Name | Type | Description |
|---|---|---|
| Belvarafenib | DRUG | Twice daily (BID), continuous dosing |
| Cobimetinib | DRUG | Once daily (QD) or three times weekly (TIW) for 21 days, 7 days off |
| Nivolumab | DRUG | Once every 4 weeks (Q4W) |
Inclusion Criteria: * ECOG Performance Status of 0 or 1 * Histologically confirmed, metastatic (recurrent or de novo Stage IV) or unresectable locally advanced (Stage III) cutaneous melanoma, that has progressed on or after treatment with anti-PD-1 or anti-PD-L1 therapy. Patients may have received ...
Top 20 of 51 competitors
Belvarafenib is an investigational small molecule being studied for the treatment of melanoma. It is currently in Phase 1 clinical development for this indication. The drug is being evaluated in patients with NRAS-mutant advanced melanoma, as detailed in an ongoing clinical trial.
Belvarafenib is a kinase inhibitor, as indicated by its '-nib' suffix. It targets kinases, which are enzymes involved in cell signaling and growth. By inhibiting these kinases, Belvarafenib aims to interfere with cancer cell proliferation in melanoma.
Belvarafenib is being developed by Roche Holding AG, a multinational healthcare company. Roche's stock is traded under the ticker symbol RHHBY. The company is conducting clinical trials to evaluate the safety and activity of Belvarafenib in melanoma patients.
Belvarafenib is currently in Phase 1 clinical development. It is an investigational drug and has not been approved by regulatory authorities. The ongoing Phase 1 trial is evaluating its safety and activity in patients with NRAS-mutant advanced melanoma.
Belvarafenib is being studied in a Phase 1 clinical trial with the identifier NCT04835805. This trial evaluates Belvarafenib as a single agent and in combination with either cobimetinib or cobimetinib plus nivolumab in patients with NRAS-mutant advanced melanoma. The trial is active but not recruiting participants.
Belvarafenib is a distinct investigational drug and is not known to be the same as any other approved medication. It is being studied under its own name in clinical trials for melanoma. No alternative names for Belvarafenib have been established in the available information.